Positions

Overview

  • I completed my Internal Medicine residency at Medstar Franklin Square Medical Center, Hematology and Oncology fellowship at East Carolina University followed by a fellowship in Investigational Cancer Therapeutics at MD Anderson Cancer Center. I have authored lung cancer focused abstracts, papers and have presented my work at national scientific meetings. In my current role as Assistant Professor at The University of Alabama at Birmingham, I focus on treating thoracic malignancies. My interests are in developing biomarker driven clinical trials for thoracic malignancies and management of immune related adverse events.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2021 Nonoperative Treatment of Large (5-7 cm), Node-Negative Non-Small Cell Lung Cancer Commonly Deviates From NCCN Guidelines. 2021
    2021 Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphomaESMO Open.  6. 2021
    2021 A Phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignanciesClinical Cancer Research.  27:3050-3060. 2021
    2021 Management of acquired resistance to ALK inhibitors: Repeat biopsy to characterize mechanisms of resistance significantly impacts clinical outcomes 2021
    2021 Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials (Nature Reviews Clinical Oncology, (2021), 18, 5, (313-319), 10.1038/s41571-021-00487-z)Nature Reviews Clinical Oncology.  18:320. 2021
    2021 COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsNature Reviews Clinical Oncology.  18:313-319. 2021
    2021 Non-small cell lung cancer, Version 2.2021 featured updates to the NCCN guidelines 2021
    2020 Dose Escalation after RTOG 0617: Recent Trends and Predictors of Radiation Doses >70 Gy in Stage III Non-Small Cell Lung Cancer from the National Cancer Database 2020
    2020 Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLCJournal of Thoracic Oncology.  15:1705-1708. 2020
    2020 Survival is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving it Concurrently or After 2020
    2020 Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignanciesESMO Open.  5. 2020
    2020 Change in Reporting of USMLE Step 1 Scores and Potential Implications for International Medical Graduates 2020
    2019 Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade 2019
    2019 Activity of brigatinib in crizotinib and ceritinib-resistant ROS1- rearranged non-small-cell lung cancer 2019
    2018 Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional databaseActa Oncologica.  57:867-872. 2018
    2018 Stage III non-small cell lung cancer: Escalation matters, but how? 2018
    2018 Frailty: The missing piece of the pre-hematopoietic cell transplantation assessment?Bone Marrow Transplantation.  53:3-10. 2018
    2016 The clinical significance of ebv DNA in the plasma and peripheral blood mononuclear cells of patients with or without ebv diseasesBlood.  127:2007-2017. 2016

    Research Overview

  • Investigative therapeutics and Immune related adverse events
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), 2009
  • Full Name

  • Aparna Hegde